Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zenocutuzumab by Merus for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...
Zenocutuzumab by Merus for Non-Small Cell Lung Cancer: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to GlobalData, Pre-Registration...
MCLA-129 by Merus for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
MCLA-129 is under clinical development by Merus and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According...
MCLA-129 by Merus for Oropharyngeal Cancer: Likelihood of Approval
MCLA-129 is under clinical development by Merus and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
MCLA-129 by Merus for Laryngeal Cancer: Likelihood of Approval
MCLA-129 is under clinical development by Merus and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Zenocutuzumab by Merus for Metastatic Breast Cancer: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase...
Zenocutuzumab by Merus for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Pre-Registration for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Pre-Registration drugs...
MCLA-145 by Merus for Merkel Cell Carcinoma: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Merkel Cell Carcinoma. According to GlobalData, Phase...
MCLA-145 by Merus for Non-Small Cell Lung Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
MCLA-145 by Merus for Glioblastoma Multiforme (GBM): Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
MCLA-145 by Merus for Anal Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Anal Cancer. According to GlobalData, Phase I...
MCLA-145 by Merus for Solid Tumor: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
MCLA-145 by Merus for Sarcomas: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs...
MCLA-145 by Merus for Gastric Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
MCLA-145 by Merus for Pancreatic Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...
MCLA-145 by Merus for Cervical Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
MCLA-145 by Merus for Colorectal Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
INCA-32459 by Merus for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
INCA-32459 is under clinical development by Merus and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
Risk adjusted net present value: What is the current valuation of Merus's MCLA-129?
MCLA-129 is a monoclonal antibody commercialized by Merus, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC)....
Risk adjusted net present value: What is the current valuation of Merus's Petosemtamab?
Petosemtamab is a monoclonal antibody commercialized by Merus, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC)....